Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorKılıç, Sevtap
dc.contributor.authorPinarli, Ferda
dc.contributor.authorÖzögül, Candan
dc.contributor.authorTaşdemir, Nicel
dc.contributor.authorSarac, Gülce Naz
dc.contributor.authorDelibaşı, Tuncay
dc.date.accessioned2022-05-11T14:35:52Z
dc.date.available2022-05-11T14:35:52Z
dc.date.issued2014
dc.identifier.issn0951-3590
dc.identifier.issn1473-0766
dc.identifier.urihttps://doi.org/10.3109/09513590.2013.860127
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8268
dc.description.abstractObjective: In female cancer survivors, the accelerated loss of primordial follicles may lead to premature ovarian failure. We investigated the protective effects of bone marrow derived mesenchymal stem cells (BMMSC) and gonadotropin releasing hormone analogue (GnRHa) against chemotherapeutic-induced ovarian toxicity in a rat model. Material and methods: Forty-eight Wistar albino female rats were divided into four groups. Group 1 was composed of rats that were given 200 mg/kg cyclophosphamide injection for each cycle (two cycles for each rat). Both cyclophosphamide and 0.4 mu g GnRHa were administered to Group 2. Cyclophosphamide and 4 million/kg BMMSC were administered to Group 3. Cyclophosphamide, GnRHa, and BMMSC were administered to Group 4. Germ cell apoptosis, DNA fragmentation and primordial follicular count were investigated with Cleave Caspase-9 and TUNEL analysis. The presence of the SRY gene on the Y chromosome in the ovary of the recipient female rats was checked with PCR. Results: Immunohistochemical staining (IHS) of Caspase-9 and TUNEL was higher in Group 1 than in Group 3 (p<0.05). Similarly, Group 4 had higher values than Group 3 (p<0.05). The presence of the SRY gene was detected in Groups 3 and 4 with the PCR analysis. The mean primordal follicle count was lowest in Group 1 and the mean primordial follicle counts were higher in Groups 2 and 3 than in Group 1. The difference between Group 1 and Group 4 was not significant. Conclusion: BMMSC therapy was found to be protective from germ cell apoptosis and DNA damage when it was used with chemotherapy regimens including alkylating agents.en_US
dc.language.isoengen_US
dc.publisherTaylor & Francis Ltden_US
dc.identifier.doi10.3109/09513590.2013.860127
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectApoptosisen_US
dc.subjectchemotherapyen_US
dc.subjectchildhood canceren_US
dc.subjectmesenchymal stem cellen_US
dc.subjectpubertyen_US
dc.subjectFunction Following Chemotherapyen_US
dc.subjectHodgkins-Diseaseen_US
dc.subjectHormone Agonisten_US
dc.subjectCanceren_US
dc.subjectFertilityen_US
dc.subjectPreventionen_US
dc.subjectFailureen_US
dc.subjectYoungen_US
dc.subjectRaten_US
dc.subjectPreservationen_US
dc.titleProtection from cyclophosphamide-induced ovarian damage with bone marrow-derived mesenchymal stem cells during pubertyen_US
dc.typearticleen_US
dc.relation.ispartofGynecological Endocrinologyen_US
dc.departmentFakülteler, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Kadın Hastalıkları ve Doğum Ana Bilim Dalıen_US
dc.authorid0000-0002-5780-8209
dc.authorid0000-0002-1034-614X
dc.identifier.volume30en_US
dc.identifier.issue2en_US
dc.identifier.startpage135en_US
dc.identifier.endpage140en_US
dc.institutionauthorTaşdemir, Nicel
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.authorscopusid55666290500
dc.authorscopusid56602651500
dc.authorscopusid6603871718
dc.authorscopusid23986422400
dc.authorscopusid56016938100
dc.authorscopusid55893004100
dc.authorwosidDELIBASI, TUNCAY/ABE-5351-2021
dc.identifier.wosWOS:000330586000012en_US
dc.identifier.scopus2-s2.0-84893044553en_US
dc.identifier.pmid24308768en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster